Transgene intends to focus resources on its core business of research and development by advancing its clinical portfolio, reorganizing its research model, and outsourcing manufacturing and pharmaceutical development activities.
The Company will apply its resources to advancing its clinical portfolio, as well as on research and development, particularly translational research. The Company plans to continue to develop innovative immunotherapies for cancer and infectious diseases by further developing its technology platforms. The Company’s strategy is to increase collaborations with academic institutions and hospitals, as well as with biopharmaceutical partners, with partnerships occurring at an earlier stage of product development.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.33 (c)||-0.30%||24 860|